Repatha

REPATHA is indicated:

• - In adults with established cardiovascular disease to reduce the risk of myocardial infarction,

stroke, and coronary revascularization

- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol

(LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous

familial hypercholesterolemia (HeFH), to reduce LDL-C

- As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and

older with HeFH, to reduce LDL-C

- As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years

and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C